Published in Proc Natl Acad Sci U S A on October 27, 2008
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
mTOR signaling at a glance. J Cell Sci (2009) 8.66
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods (2009) 4.12
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell (2010) 3.79
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal (2012) 3.40
AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab (2012) 3.35
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy (2012) 2.87
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol (2015) 2.85
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Amino acids and mTORC1: from lysosomes to disease. Trends Mol Med (2012) 2.38
Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci (2009) 2.35
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 2.29
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature (2016) 1.90
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature (2014) 1.84
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res (2010) 1.74
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene (2014) 1.69
A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe (2013) 1.69
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity (2013) 1.56
Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A (2010) 1.53
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A (2013) 1.53
Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res (2011) 1.53
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle (2011) 1.44
Rapamycin: one drug, many effects. Cell Metab (2014) 1.41
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. J Neurosci (2012) 1.39
Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther (2011) 1.38
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol (2014) 1.33
TSC1/TSC2 signaling in the CNS. FEBS Lett (2011) 1.31
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal (2016) 1.30
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS One (2013) 1.29
mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest (2012) 1.27
mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLoS One (2012) 1.25
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
Hot topics in aging research: protein translation, 2009. Aging Cell (2009) 1.24
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res (2010) 1.23
Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget (2015) 1.23
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23
The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis. Cell Death Differ (2010) 1.22
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood (2011) 1.20
PI3K-mTORC1 attenuates stress response by inhibiting cap-independent Hsp70 translation. J Biol Chem (2010) 1.20
Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res (2012) 1.20
mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol (2011) 1.19
Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol (2012) 1.18
Raptor is phosphorylated by cdc2 during mitosis. PLoS One (2010) 1.17
Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 1.16
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res (2013) 1.16
Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood (2010) 1.15
mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci U S A (2011) 1.14
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood (2012) 1.14
Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer (2011) 1.14
Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol (2012) 1.13
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One (2011) 1.12
Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. Sci Signal (2013) 1.12
Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem (2011) 1.12
mTOR Signaling in Growth, Metabolism, and Disease. Cell (2017) 1.10
Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Mol Cell Biol (2010) 1.09
Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury. Exp Neurol (2011) 1.09
Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci U S A (2013) 1.08
Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. J Gerontol A Biol Sci Med Sci (2013) 1.08
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle (2013) 1.08
TOR signaling never gets old: aging, longevity and TORC1 activity. Ageing Res Rev (2010) 1.07
Targeting TOR dependence in cancer. Oncotarget (2010) 1.07
The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) (2012) 1.05
Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics (2013) 1.05
PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol (2011) 1.05
mTOR activates the VPS34-UVRAG complex to regulate autolysosomal tubulation and cell survival. EMBO J (2015) 1.04
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol (2010) 1.04
Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein. J Biol Chem (2013) 1.03
TOR signaling in growth and metabolism. Cell (2006) 35.29
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 9.40
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 8.51
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev (1998) 6.89
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J (1996) 6.01
S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science (2006) 5.94
Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J (1999) 4.65
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J (1992) 3.66
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J (2004) 3.29
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem (2005) 2.57
Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol (2001) 1.62
Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol (2002) 1.42
Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist (2007) 1.34
Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem (2001) 1.28
Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene (2005) 1.08
Control of PHAS-I phosphorylation in 3T3-L1 adipocytes: effects of inhibiting protein phosphatases and the p70S6K signalling pathway. Diabetologia (1997) 1.03
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev (2004) 9.54
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell (2005) 6.71
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol (2004) 5.46
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A (2004) 5.16
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol (2008) 4.92
RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
MAPK signal specificity: the right place at the right time. Trends Biochem Sci (2006) 3.96
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol (2005) 3.89
Identification of a conserved motif required for mTOR signaling. Curr Biol (2002) 3.78
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell (2008) 3.43
ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell (2010) 3.03
Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol (2005) 2.88
Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem (2005) 2.84
mTOR, translational control and human disease. Semin Cell Dev Biol (2004) 2.77
The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric neoplasm. Gastrointest Endosc (2005) 2.76
The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell (2013) 2.70
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol (2008) 2.58
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle (2009) 2.45
A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell (2010) 2.40
Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res (2002) 2.37
mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J (2010) 2.35
Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol (2003) 2.32
A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol (2004) 2.30
Transmembrane receptor DCC associates with protein synthesis machinery and regulates translation. Cell (2010) 2.23
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem (2003) 2.12
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell (2013) 1.99
Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A (2011) 1.90
Regulation and function of the RSK family of protein kinases. Biochem J (2012) 1.90
Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms? Gastrointest Endosc (2012) 1.90
SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol (2004) 1.90
Clinical outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Surg Endosc (2009) 1.83
Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol (2004) 1.81
Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc (2011) 1.78
PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol (2004) 1.78
The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci (2008) 1.75
ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem (2010) 1.74
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A (2008) 1.69
Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc (2009) 1.68
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Incidence and management of colonoscopic perforations in Korea. Digestion (2009) 1.58
Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem (2009) 1.53
Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol Cell (2012) 1.50
PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol (2003) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett (2005) 1.48
Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo. Curr Biol (2005) 1.46
Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol (2004) 1.43
Graded mitogen-activated protein kinase activity precedes switch-like c-Fos induction in mammalian cells. Mol Cell Biol (2005) 1.42
Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells (2013) 1.42
Clinical features and prognosis of early colorectal cancer treated by endoscopic mucosal resection. J Gastroenterol Hepatol (2011) 1.41
The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol (2005) 1.38
Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell (2008) 1.33
TORgeting oncogene addiction for cancer therapy. Cancer Cell (2006) 1.30
Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer. J Surg Oncol (2009) 1.26
Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. Genes Dev (2014) 1.22
ERK-MAPK drives lamellipodia protrusion by activating the WAVE2 regulatory complex. Mol Cell (2011) 1.22
Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res (2009) 1.20
Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J Biol Chem (2005) 1.17
p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem (2009) 1.16
Is endoscopic ultrasonography indispensable in patients with early gastric cancer prior to endoscopic resection? Surg Endosc (2010) 1.16
PHLPPing it off: phosphatases get in the Akt. Mol Cell (2007) 1.14
Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res (2004) 1.14
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res (2008) 1.14
Characterizing the interaction of the mammalian eIF4E-related protein 4EHP with 4E-BP1. FEBS Lett (2004) 1.12
Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer. Surg Endosc (2012) 1.12
Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res (2008) 1.11
Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett (2007) 1.10
Protein kinase A activation promotes plasma membrane insertion of DCC from an intracellular pool: A novel mechanism regulating commissural axon extension. J Neurosci (2004) 1.10
Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem (2002) 1.08